Amr El-Shehaby

Prof. Dr. Amr El-Shehaby

Ain Shams University, Cairo, Al Qāhirah, Egypt

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2017 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
GMGautam U Mehta
Gautam U Mehta
DDDale Ding
Dale Ding
MPMohana Rao Patibandla
Mohana Rao Patibandla
HKHideyuki Kano
Hideyuki Kano
NSNathaniel Sisterson
Nathaniel Sisterson
JSJason P. Sheehan
Jason P. Sheehan
Context Cushing’s disease (CD) due to ACTH-secreting pituitary tumors can be a management challenge. Objective To better understand the outcomes of stereotactic radiosurgery (SRS) for CD and define its role in management. Design International, multicenter, retrospective cohort analysis. Setting Ten medical centers participating in the International Gamma Knife Research Foundation (IGKRF). Patients Patients with CD with greater than 6 months endocrine follow-up. Intervention SRS using Gamma Knife radiosurgery. Main outcome measures The primary outcome was control of hypercortisolism (defined as normalization of free urinary cortisol). Radiologic response and adverse radiation effects were recorded. Results 278 patients met inclusion criteria, with mean follow-up of 5.6 years (0.5-20.5 years). Twenty-two patients received SRS as a primary treatment for CD. Mean margin dose was 23.7 Gy. Cumulative initial control of hypercortisolism was 80% at 10 years. Mean time to cortisol normalization was 14.5 months. Recurrences occurred in 18% with initial cortisol normalization. Overall, the rate of durable control of hypercortisolism was 64% at 10 years, and 68% among patients who received SRS as a primary treatment. Adverse radiation effects included hypopituitarism (25%) and cranial neuropathy (3%). Visual deficits were related to treatment of tumor within the suprasellar cistern (P=0.01), while both visual (P<0.0001) and non-visual cranial neuropathy (P=0.02) were related to prior pituitary irradiation. Conclusions SRS for CD is well-tolerated and frequently results in control of hypercortisolism. However, recurrences can occur. SRS should be considered for patients with persistent hypercortisolism after pituitary surgery and as a primary treatment in those unfit for surgery. Long-term endocrine follow-up is essential after SRS.

26 August 2009 in Acta Neurochirurgica
Verified
Journal Article
Closed access
PDF file
AGahmed galal
ahmed galal
AFAhmed Faisal
Ahmed Faisal
MAMohamed Al-Werdany
Mohamed Al-Werdany
AEAmr El-Shehaby
Amr El-Shehaby
TLTarek Lotfy
Tarek Lotfy
HMHusein Moharram
Husein Moharram

9 November 2018 in Journal of Neurosurgery
Verified
Journal Article
Closed access
PDF file
DCDiogo Cordeiro
Diogo Cordeiro
ZXZhiyuan Xu
Zhiyuan Xu
GMGautam U. Mehta
Gautam U. Mehta
DDDale Ding
Dale Ding
MVMary Lee Vance
Mary Lee Vance
JSJason P. Sheehan
Jason P. Sheehan
OBJECTIVE: Recurrent or residual adenomas are frequently treated with Gamma Knife radiosurgery (GKRS). The most common complication after GKRS for pituitary adenomas is hypopituitarism. In the current study, the authors detail the timing and types of hypopituitarism in a multicenter, international cohort of pituitary adenoma patients treated with GKRS.METHODS: Seventeen institutions pooled clinical data obtained from pituitary adenoma patients who were treated with GKRS from 1988 to 2016. Patients who had undergone prior radiotherapy were excluded. A total of 1023 patients met the study inclusion criteria. The treated lesions included 410 nonfunctioning pituitary adenomas (NFPAs), 262 cases of Cushing’s disease (CD), and 251 cases of acromegaly. The median follow-up was 51 months (range 6–246 months). Statistical analysis was performed using a Cox proportional hazards model to evaluate factors associated with the development of new-onset hypopituitarism.RESULTS: At last follow-up, 248 patients had developed new pituitary hormone deficiency (86 with NFPA, 66 with CD, and 96 with acromegaly). Among these patients, 150 (60.5%) had single and 98 (39.5%) had multiple hormone deficiencies. New hormonal changes included 82 cortisol (21.6%), 135 thyrotropin (35.6%), 92 gonadotropin (24.3%), 59 growth hormone (15.6%), and 11 vasopressin (2.9%) deficiencies. The actuarial 1-year, 3-year, 5-year, 7-year, and 10-year rates of hypopituitarism were 7.8%, 16.2%, 22.4%, 27.5%, and 31.3%, respectively. The median time to hypopituitarism onset was 39 months.In univariate analyses, an increased rate of new-onset hypopituitarism was significantly associated with a lower isodose line (p = 0.006, HR = 8.695), whole sellar targeting (p = 0.033, HR = 1.452), and treatment of a functional pituitary adenoma as compared with an NFPA (p = 0.008, HR = 1.510). In multivariate analyses, only a lower isodose line was found to be an independent predictor of new-onset hypopituitarism (p = 0.001, HR = 1.38).CONCLUSIONS: Hypopituitarism remains the most common unintended effect of GKRS for a pituitary adenoma. Treating the target volume at an isodose line of 50% or greater and avoiding whole-sellar radiosurgery, unless necessary, will likely mitigate the risk of post-GKRS hypopituitarism. Follow-up of these patients is required to detect and treat latent endocrinopathies.

2 March 2023 in Neurosurgery
Verified
Journal Article
Open access
OBOthman Bin-Alamer
Othman Bin-Alamer
AFAndrew Faramand
Andrew Faramand
NANorah A. Alarifi
Norah A. Alarifi
ZWZhishuo Wei
Zhishuo Wei
AMArka N. Mallela
Arka N. Mallela
HAHussam Abou-Al-Shaar
Hussam Abou-Al-Shaar
BACKGROUND: Vestibular schwannomas (VSs) related to neurofibromatosis type 2 (NF2) are challenging tumors. The increasing use of stereotactic radiosurgery (SRS) necessitates further investigations of its role and safety. OBJECTIVE: To evaluate tumor control, freedom from additional treatment (FFAT), serviceable hearing preservation, and radiation-related risks of patients with NF2 after SRS for VS. METHODS: We performed a retrospective study of 267 patients with NF2 (328 VSs) who underwent single-session SRS at 12 centers participating in the International Radiosurgery Research Foundation. The median patient age was 31 years (IQR, 21-45 years), and 52% were male. RESULTS: A total of 328 tumors underwent SRS during a median follow-up time of 59 months (IQR, 23-112 months). At 10 and 15 years, the tumor control rates were 77% (95% CI: 69%-84%) and 52% (95% CI: 40%-64%), respectively, and the FFAT rate were 85% (95% CI: 79%-90%) and 75% (95% CI: 65%-86%), respectively. At 5 and 10 years, the serviceable hearing preservation rates were 64% (95% CI: 55%-75%) and 35% (95% CI: 25%-54%), respectively. In the multivariate analysis, age (hazards ratio: 1.03 [95% CI: 1.01-1.05]; P = .02) and bilateral VSs (hazards ratio: 4.56 [95% CI: 1.05-19.78]; P = .04) were predictors for serviceable hearing loss. Neither radiation-induced tumors nor malignant transformation were encountered in this cohort. CONCLUSION: Although the absolute volumetric tumor progression rate was 48% at 15 years, the rate of FFAT related to VS was 75% at 15 years after SRS. None of the patients with NF2-related VS developed a new radiation-related neoplasm or malignant transformation after SRS.

1 December 2016 in Journal of Neurosurgery
Verified
Journal Article
Closed access
AEAmr El-Shehaby
Amr El-Shehaby
WRWael A. Reda
Wael A. Reda
KKKhaled M. Abdel Karim
Khaled M. Abdel Karim
REReem M. Emad Eldin
Reem M. Emad Eldin
ANAhmed M. Nabeel
Ahmed M. Nabeel
OBJECTIVE: Because of their critical and central location, it is deemed necessary to fractionate when considering irradiating optic pathway/hypothalamic gliomas. Stereotactic fractionated radiotherapy is considered safer when dealing with gliomas in this location. In this study, the safety and efficacy of single-session stereotactic radiosurgery for optic pathway/hypothalamic gliomas were reviewed.METHODS: Between December 2004 and June 2014, 22 patients with optic pathway/hypothalamic gliomas were treated by single-session Gamma Knife radiosurgery. Twenty patients were available for follow-up for a minimum of 1 year after treatment. The patients were 5 to 43 years (median 16 years) of age. The tumor volume was 0.15 to 18.2 cm3 (median 3.1 cm3). The prescription dose ranged from 8 to 14 Gy (median 11.5 Gy).RESULTS: The mean follow-up period was 43 months. Five tumors involved the optic nerve only, and 15 tumors involved the chiasm/hypothalamus. Two patients died during the follow-up period. The tumors shrank in 12 cases, remained stable in 6 cases, and progressed in 2 cases, thereby making the tumor control rate 90%. Vision remained stable in 12 cases, improved in 6 cases, and worsened in 2 cases in which there was tumor progression. Progression-free survival was 83% at 3 years.CONCLUSIONS: The initial results indicate that single-session Gamma Knife radiosurgery is a safe and effective treatment option for optic pathway/hypothalamic gliomas.

1 August 2018 in World Neurosurgery
Verified
Journal Article
Closed access
MSMatthew J. Shepard
Matthew J. Shepard
GMGautam U. Mehta
Gautam U. Mehta
ZXZhiyuan Xu
Zhiyuan Xu
HKHideyuki Kano
Hideyuki Kano
NSNathaniel Sisterson
Nathaniel Sisterson
JSJason P. Sheehan
Jason P. Sheehan